<DOC>
	<DOCNO>NCT01001754</DOCNO>
	<brief_summary>Interleukin 29 ( IL-29 ) substance produce body help fight viral infection . The purpose study evaluate safety antiviral effect several different dos PEG-rIL-29 ( man-made form IL-29 ) give combination daily oral dos ribavirin ( antiviral drug ) subject hepatitis C infection receive prior treatment disease .</brief_summary>
	<brief_title>Efficacy Safety Study PEG-rIL-29 Plus Ribavirin Treat Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>PEG-rIL-29 ( also know PEG-interferon lambda ) unique Type III interferon molecule demonstrate antiviral activity administer weekly 4 week treatment-relapsed treatment-naive subject genotype 1 hepatitis C virus ( HCV ) infection . Because PEG-rIL-29 bind unique receptor limit distribution receptor interferon ( IFN ) -α , may potential treat HCV without treatment-limiting side effect associate IFN-α-based therapy . The purpose Phase 2a/b randomize , control , multicenter study compare safety efficacy PEG-rIL-29 peginterferon alfa-2a , administer subcutaneously weekly 48 week combination daily oral ribavirin , treatment-naive subject chronic genotype 1 , 2 , 3 , 4 HCV infection . The initial part study ( Phase 2a ) conduct open-label study ; second part study ( Phase 2b ) conduct blind study . The information provide listing specific Phase 2b portion study . In addition , two small open-label substudies conduct evaluate efficacy 24-week treatment PEG-rIL-29 ribavirin subject HCV genotype 1 particular genetic polymorphism associate favorable response ( n=60 ) evaluate efficacy 16-week treatment PEG-rIL-29 ribavirin subject HCV genotype 2 3 ( n=30 ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>No prior therapy chronic HCV , 2 week singleagent therapy directacting antiviral agent , include limited , protease polymerase inhibitor HCV genotype 1 , 2 , 3 , 4 HCV RNA ≥100,000 IU/mL ALT AST ≤5.0 × ULN Documented absence cirrhosis Able comprehend investigational nature study sign inform consent form Mixed genotype HCV infection Current prior history decompensated liver disease Received investigational drug , include directacting antiviral agent , within 60 day prior receive study drug Positive test hepatitis B surface antigen , human immunodeficiency virus ( HIV ) 1 , HIV2 antibody screen Active substance abuse , alcohol , inhale injected drug , within 6 month Additional inclusion exclusion criterion specify protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>PEGylated recombinant interleukin 29</keyword>
	<keyword>PEG-interferon lambda</keyword>
	<keyword>Interleukin 29</keyword>
	<keyword>Virus</keyword>
	<keyword>Infection</keyword>
	<keyword>Liver Diseases</keyword>
</DOC>